In the latest trading session, 0.53 million Avenue Therapeutics Inc (NASDAQ:ATXI) shares changed hands as the company’s beta touched -0.17. With the company’s most recent per share price at $0.45 changed hands at -$0.4 or -47.19% at last look, the market valuation stands at $0.92M. ATXI’s current price is a discount, trading about -2733.33% off its 52-week high of $12.75. The share price had its 52-week low at $0.72, which suggests the last value was -60.0% down since then. When we look at Avenue Therapeutics Inc’s average trading volume, we note the 10-day average is 61340.0 shares, with the 3-month average coming to 418.61K.
Analysts gave the Avenue Therapeutics Inc (ATXI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATXI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Avenue Therapeutics Inc (NASDAQ:ATXI) trade information
Instantly ATXI was in red as seen in intraday trades today. With action -53.61%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -77.50%, with the 5-day performance at -53.61% in the red. However, in the 30-day time frame, Avenue Therapeutics Inc (NASDAQ:ATXI) is -66.91% down. Looking at the short shares, we see there were 59696.0 shares sold at short interest cover period of 0.65 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 96.25% from its recent market value. According to analyst projections, ATXI’s forecast low is 12 with 12 as the target high. To hit the forecast high, the stock’s price needs a -2566.67% plunge from its current level, while the stock would need to soar -2566.67% for it to hit the projected low.
Avenue Therapeutics Inc (ATXI) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 50.07%. The 2025 estimates are for Avenue Therapeutics Inc earnings to increase by 91.51%, but the outlook for the next 5-year period is at 70.75% per year.
Avenue Therapeutics Inc (NASDAQ:ATXI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 25.23% of Avenue Therapeutics Inc shares while 15.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 20.50%.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund. With 6.59 shares estimated at $3034.0 under it, the former controlled 0.32% of total outstanding shares. On the other hand, Fidelity Series Total Market Index Fund held about 0.08% of the shares, roughly 1.58 shares worth around $728.0.
